| 7.12 0 (0%) | 03-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.31 | 1-year : | 9.71 |
| Resists | First : | 7.11 | Second : | 8.31 |
| Pivot price | 6.52  |
|||
| Supports | First : | 5.55 |
Second : | 4.58 |
| MAs | MA(5) : | 7.11 | MA(20) : | 6.19 |
| MA(100) : | 5.51 |
MA(250) : | 5.15 |
|
| MACD | MACD : | 0.5  |
Signal : | 0.4 |
| %K %D | K(14,3) : | 100 | D(3) : | 100 |
| RSI | RSI(14): 70.9 | |||
| 52-week | High : | 7.11 | Low : | 2.06 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FSTX ] has closed below upper band by 30.0%. Bollinger Bands are 54.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.14 - 7.17 | 7.17 - 7.2 |
| Low: | 7.02 - 7.07 | 7.07 - 7.11 |
| Close: | 7.05 - 7.13 | 7.13 - 7.19 |
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Tue, 07 Mar 2023
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma - GlobeNewswire
Wed, 20 Jul 2022
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology ... - GlobeNewswire
Tue, 12 Jul 2022
Has EDAP TMS (EDAP) Outpaced Other Medical Stocks This Year? - Yahoo Movies UK
Thu, 23 Jun 2022
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and ... - GlobeNewswire
Wed, 05 Jan 2022
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno ... - GlobeNewswire
Wed, 01 Sep 2021
Will The Trials Of Bispecific Antibodies Add Shine To F-star Therapeutics? - RTTNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 44.9 (%) |
| Shares Short | 1,230 (K) |
| Shares Short P.Month | 910 (K) |
| EPS | -1.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.58 |
| Profit Margin | -211.4 % |
| Operating Margin | -162.3 % |
| Return on Assets (ttm) | -21.7 % |
| Return on Equity (ttm) | -60.9 % |
| Qtrly Rev. Growth | 49.7 % |
| Gross Profit (p.s.) | 0.96 |
| Sales Per Share | 0.96 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -3.9 |
| PEG Ratio | 0 |
| Price to Book value | 2.74 |
| Price to Sales | 7.38 |
| Price to Cash Flow | -4.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2020-11-22 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|